

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

VOLUNTARY ANNOUNCEMENT

STRATEGIC COOPERATION AGREEMENT WITH JENSCARE SCIENTIFIC

This announcement is made by LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that on 6 February 2023, the Company entered into a strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) with Jenscare Scientific Co., Ltd. (“**Jenscare Scientific**”) in respect of potential cooperation including but not limited to business development, project investments and financing in mainland China and overseas.

COOPERATION FIELDS

Pursuant to the Strategic Cooperation Agreement, the Company and Jenscare Scientific shall explore a long-term and stable strategic cooperation relationship. In particular:

1. the Company shall assist Jenscare Scientific in the completion of clinical trials and product registrations in mainland China and overseas;
2. the parties shall cooperate strategically in the sales and marketing of products, including but not limited to in mainland China, Asia Pacific, Europe, North America and Latin America;

3. the parties shall cooperate and assist each other in the research and development of globally innovative products;
4. the parties shall cooperate in the development of a digitalized and automated production supply chain system in the long term; and
5. the parties shall share potential investments and merger and acquisition resources that will help the other party's product strategy, and promote the long term development of the parties.

If the parties agree to cooperate on specific projects in relation to the above areas in the future, the Company and Jenscare Scientific will enter into separate agreements which will set out the specific terms and conditions according to the principles under the Strategic Cooperation Agreement.

INFORMATION ON JENSCARE SCIENTIFIC

Jenscare Scientific is a medical device company dedicated to the development of interventional products for the treatment of structural heart diseases. Established in 2011, it has developed a series of treatment solutions targeting different types of structural heart diseases, including tricuspid valve diseases, aortic valve diseases, mitral valve diseases and heart failure. The shares of Jenscare Scientific are listed on The Stock Exchange of Hong Kong Limited (stock code: 9877).

INFORMATION ON THE GROUP

The Group is a leading developer, manufacturer and marketer of advanced minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The Group currently has distributors in countries across Asia, Africa, North America, South America and Europe, with a sales network across more than 100 countries and/or regions.

REASONS FOR AND BENEFITS OF THE STRATEGIC COOPERATION AGREEMENT

Having considered the overall strengths in the respective businesses and products, brand influence and ample resources of both parties to the Strategic Cooperation Agreement, the Company believes that the cooperation with Jenscare Scientific under the Strategic Cooperation Agreement will create synergy with the Group's businesses and international strategy and provide the Group with the chance to generate further revenue with an aim to enhance the profitability of the Group as a whole.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, save as being a shareholder holding approximately 1.35% of the total issued share capital of Jenscare Scientific as of the date of this announcement, the Company and its ultimate beneficial owners are third parties independent of Jenscare Scientific and its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited).

Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui

Executive Director, Chairman and Chief Executive Officer

Hong Kong, 6 February 2023

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive directors; Mr. JIANG Feng being non-executive director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive directors.